The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of pharmacokinetic modeling to optimize direct inhibition of the "undruggable" target EWS-FLI1 of Ewing sarcoma.
Jeffrey Toretsky
No relevant relationships to disclose
S. Peter Hong
No relevant relationships to disclose
S. Ellen Gamble
No relevant relationships to disclose
Sung-Hyeok Hong
No relevant relationships to disclose
Christina L. Kobs
No relevant relationships to disclose
Karen E. Elsass
No relevant relationships to disclose
Natalie L. South
No relevant relationships to disclose
Stephen J. Summer
No relevant relationships to disclose
Philip J. Monroe
No relevant relationships to disclose
Aykut Uren
No relevant relationships to disclose